Inherited lipid metabolism disorder
Therapeutic area
Metabolic Disease
Rare disease
Yes
- Definition
- An inherited metabolic disorder caused by an enzyme deficiency, resulting in an inability to oxidize fatty acids for energy production.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Inherited lipid metabolism disorder
- Therapeutic area
- Metabolic Disease
- inherited lipid metabolism disorder
- Depressive Episode, Dyslipidemia
- Dyslipidaemia
- DYSLIPIDEMIA
- Dyslipidemia (Fredrickson Type Ⅱa)
- Dyslipidemia (Fredrickson Type Ⅱb)
- Dyslipidemia, Hypercholesterolemia
- Essential Hypertension With Stable Angina and Dyslipidemia
- Hypercholesterolemia, Dyslipidemia
- Hypertension and Dyslipidemia
- Hypertension, Dyslipidemia
- Lipid Metabolism Disorder
- Lipid Metabolism Disorders
- Metabolism Disorder, Lipid
- Mild Dyslipidemia
- Subjects With Hyperlipidemia, Dyslipidemia
- disorder of lipid metabolism
- All therapeutic areas
- Metabolic Disease
Sources for recorded values
- Severity
- Severe
- Genetic
- Hereditary
- Inborn Error of Metabolism
Sources for recorded values
- MONDO ID
- MONDO:0002525
- Parent condition
- MONDO:0019052
Related records
Broader conditions (8)
- Disease
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Human disease
- Inborn errors of metabolism
- Metabolic disease
Narrower conditions (311)
- 3-hydroxy-3-methylglutaric aciduria
- 3-hydroxy-3-methylglutaryl-CoA synthase deficiency
- 3-hydroxyacyl-CoA dehydrogenase deficiency
- 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome
- 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency
- Abetalipoproteinemia
- Acid sphingomyelinase deficiency
- Acyl-CoA binding domain containing protein 5 deficiency
- Acyl-CoA dehydrogenase 9 deficiency
- Acyl-CoA dehydrogenase deficiency
- Adult Krabbe disease
- Adult neuronal ceroid lipofuscinosis
- Adult neuronal ceroid lipofuscinosis 1
- Adult neuronal ceroid lipofuscinosis 5
- Alkylglycerone-phosphate synthase deficiency
- Apparent mineralocorticoid excess
- ASAH1-related sphingolipidosis
- Auditory neuropathy-optic atrophy syndrome
- Autosomal recessive cerebellar ataxia with late-onset spasticity
- Autosomal recessive complex spastic paraplegia due to kennedy pathway dysfunction
Trials (1,406)
- 'Ai Pono Cooking Demonstrations
- "Perfect Heartio" Drink and Cardiovascular Health
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
- 12 Weeks of Resistance Band Exercise Impacts on Metabolic Syndrome Progression in Postmenopausal Women
- 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
- 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
- 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
- 4D-310 in Adults With Fabry Disease and Cardiac Involvement
- A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
- A Cholesterol Lowering Therapy of Focused Power Ultrasound Mediated Perirenal Fat Ablation
- A Clinical Pharmacology Study of K-877 Controlled Release Tablet
- A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in Thailand
- A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers
- A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
- A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
- A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
- A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391
Approved drugs (2)
- Cetilistat
- Inclisiran
Drugs in development (115)
- Acetylcarnitine Phase 3
- Alendronate sodium Phase 1
- Alendronic acid Phase 1
- Alirocumab Phase 3
- Amlodipine Phase 3
- Amlodipine maleate Phase 3
- Anacetrapib Phase 3
- Antimony Phase 3
- Apabetalone Phase 2
- Aspirin Phase 3
- Atorvastatin Phase 3
- Atorvastatin calcium Phase 3
- Bempedoic acid Phase 2
- Berberine Phase 3
- Berberine sulfate Phase 3
- BMS-770767 Phase 2
- BMS-816336 Phase 1
- BMS-823778 Phase 2
- Bococizumab Phase 3
- Cannabidiol Phase 2
Other linked drugs (20)
- Amlodipine besylate
- Avexitide
- Bepotastine besylate
- Bisoprolol
- Carvedilol
- Cinnamon
- Exenatide
- Fish oil triglycerides
- Garlic
- Ginger
- Glucagon-like peptide 1
- Insulin human
- Liraglutide
- Metoprolol
- Metoprolol fumarate
- Odevixibat
- Olmesartan medoxomil
- Propranolol
- Sitagliptin
- Tenofovir disoproxil fumarate